Alemtuzumab
Paroxysmal Nocturnal Hemoglobinuria
Explore 6 assets in Paroxysmal Nocturnal Hemoglobinuria →Floatz Rating
B61/100
Confidence
Indicative
Sponsor
University of Arizona
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
46High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00997386CT.gov Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States | — | Completed | — | — | — |
NCT00566696CT.gov Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Paroxysmal Nocturnal Hemoglobinuria
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Alemtuzumab (this asset) | University of Arizona | P2 | B · 61 |
| Muromonab-Cd3 | St. Jude Children's Research Hospital | P3 | BB |
| Thiotepa | Fred Hutchinson Cancer Center | P3 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P3 | BB |
| Fludarabine | Fred Hutchinson Cancer Center | P3 | BB |
| Melphalan | Roswell Park Cancer Institute | P3 | BB |
| Rituximab | St. Jude Children's Research Hospital | P3 | BB |
| Eculizumab | AO GENERIUM | P3 | BB |
| Tacrolimus | Fred Hutchinson Cancer Center | P2 | B |
+11 more in the Paroxysmal Nocturnal Hemoglobinuria cohort
Other indications for Alemtuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P4 | BBB · 73 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2 | BB · 71 |
| Chronic Myeloid Leukemia | — | P2/3 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Alemtuzumab in Paroxysmal Nocturnal Hemoglobinuria. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-human-rat-monoclonal-campath-1h-gamma1-chain-anti-human-antigen-cd52-disulfide-with-human-rat-monoclonal-campath-1h-light-chain-dimer-paroxysmal-nocturnal-hemoglobinuria-42803
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →